Profile: Genentech Inc. manufactures multiple biotherapeutics for critical medical conditions in the areas of oncology, immunology, and disorders of tissue growth. Our products include avastin®, herceptin®, rituxan®, tarceva®, raptiva®, xolair®, lucentis®, nutropin® and pulmozyme®. Avastin® is an approved therapy designed to inhibit angiogenesis, the process by which new blood vessels develop and carry vital nutrients to a tumor. This therapy is approved, in combination with intravenous 5-fluorouracil-based (5-FU) chemotherapy, for first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum. It can also be used in combination with carboplatin and paclitaxel for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC). Herceptin® is the first humanized antibody approved for the treatment of HER2-positive metastatic breast cancer. This antibody is designed to target and block the function of HER2 protein overexpression. Activase® is a tissue plasminogen activator produced by recombinant DNA technology. This is approved for treating acute myocardial infarction (AMI), or heart attacks, acute ischemic stroke, and acute, massive pulmonary embolism.
17 Products/Services (Click for related suppliers)
|•||Anti-CD11a Antibody||•||Anti-CD20 Antibody||•||Anti-IgE Antibody|
|•||Biopharmaceutical Drugs||•||Biopharmaceuticals for Acute Myocardial Infarction||•||Biopharmaceuticals for Asthma|
|•||Biopharmaceuticals for Metastatic Breast Cancer||•||Biopharmaceuticals for Metastatic Carcinoma||•||Biopharmaceuticals for Metastatic non-small Cell L...|
|•||Biopharmaceuticals for Non-Hodgkin's Lymphoma||•||Biopharmaceuticals for Plaque Psoriasis||•||Growth Hormone|
|•||Liquid Formulation Growth Hormone||•||New Drug Discovery||•||Single-bolus Thrombolytic Agent|
|•||Thrombolytic Agent||•||Tissue-plasminogen Activator|